Renova is exploring new therapeutic opportunities that have the potential to expand the use of Renova’s gene therapy platform to include several pathologies associated with diabetes and heart failure.

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus

Renova Therapeutics Inc, a leader in the development of gene therapies for cardiovascular diseases and diabetes, announced the appointment of Dr. Vijay Mahant to the position of CEO, effective as of Sept. 16, 2021.

The National Medical Association 110th Annual Convention and Scientific Assembly in New Orleans, Louisiana

Healthy Heart's medical director, Dr. Suresh Gadasalli, says the painless treatment has reduced or eliminated angina pain, fatigue, and shortness of breath for hundreds of the center's patients

New Aquapheresis treatment can replace expensive diuretic medications for patients with fluid overload who do not respond to diuretics.

More than five million Americans are suffering from this disease but many people are still unaware of this condition. Many people are only aware of high blood pressure which is they fail to recognize the important signs of congestive heart disease.